相关实验视频

Updated: Feb 24, 2026

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

多维分析揭示了PDK4作为瘤生物标志物和免疫治疗点的潜力

Yaxing Deng¹, Xin Wang², Mei Zeng¹

¹Department of Emergency Medicine, The Affiliated Hospital of Southwest Medical University, 25 Taiping Street, Jiangyang District, Luzhou, 646000, Sichuan, China.

Discover oncology

|February 23, 2026

概括

酸盐脱酶激酶4 (PDK4) 显示出作为诊断和预后的泛癌生物标志物具有前途. 它在瘤中的降低调节表明它有可能成为免疫疗法点,改善患者的治疗结果.

科学领域:

在瘤学瘤学.
生物化学生物化学
免疫学免疫学免疫学

背景情况:

酸盐脱酶激酶4 (PDK4) 在细胞代谢中发挥作用.
了解PDK4在癌症中的功能对于开发新的治疗策略至关重要.

研究的目的:

调查PDK4在泛癌症中的临床意义.
评估PDK4作为潜在的瘤生物标志物和免疫治疗点.

主要方法:

对PDK4表达,诊断和预后价值的公共数据库 (HPA,TCGA,GTEx) 的分析.
评估免疫特征,遗传变化和免疫治疗反应.
分子对接用于有针对性的药物预测.

主要成果:

在大多数癌症中,PDK4的下调,但具有很高的诊断效率 (AUC > 0.7).
PDK4表达是整体存活的独立预后因素,与免疫透相关.
在接受抗PD-L1治疗的患者中,高PDK4表达与改善无进展生存相关.

结论:

PDK4是一种有价值的泛癌诊断和预后生物标志物.
PDK4代表了癌症免疫治疗的潜在目标.
这些发现支持个性化癌症治疗策略.

关键词:

免疫治疗是一种免疫疗法.代谢过程中的代谢.在PDK4中使用PDK4.胰腺癌是一种癌症.

更多相关视频

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

相关概念视频

Interactions Between Signaling Pathways

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...